Lumenis, an aesthetic and eye care solutions provider, has launched the FoLix fractional laser for hair loss treatment in the US.

FoLix is a non-ablative fractional laser device for safe, effective, natural hair loss treatment for women and men.

The device recently received regulatory clearance from the US Food and Drug Administration (FDA).

FoLix uses fractional laser and Lumenis’ proprietary technology designed specifically for hair.  

Lumenis said that the device offers a transformative solution for individuals with Fitzpatrick skin types I to IV, who need treatment for hair loss.

Lumenis CEO Tzipi Ozer-Armon said: “At Lumenis, we’re committed to transforming lives through science and innovation. FoLix is about more than just hair; it’s about having the self-confidence to live life to the fullest.

“We are eager to collaborate with providers across the US to extend the influence and accessibility of this groundbreaking solution.”

The fractional laser can show visible outcomes within four to six monthly sessions, the aesthetic solutions provider claimed.

In addition, the therapy is free from chemicals, needles, anaesthesia, and surgery, and has no downtime.

The technology triggers the body’s innate mechanisms to activate hair follicles by delivering targeted laser pulses.

In Lumenis’ pre-clinical and clinical studies, the laser device demonstrated a favourable impact on hair growth, enhancing scalp hair appearance and boosting hair count significantly.

WCMC dermatology clinical professor Neil Sadick said: “With hair loss becoming a growing concern, FoLix emerges as a pivotal innovation for both patients and providers.

“FoLix offers a unique opportunity to help those suffering from hair loss through short monthly sessions and with minimal discomfort and no downtime.”

Lumenis, a portfolio company of EQT Private Capital Asia, has been engaged in developing energy-based technologies such as laser, intense pulsed light (IPL), and radiofrequency (RF).